aureus vaccine and pipeline R&D programmes.' This investment will fund exciting stages of development for Absynth’s S. This brings the total awarded to Absynth since 2012 to £175,000 in two grants from the TSB.įiona Marston, chief executive of Absynth Biologics which is based in Sheffield, said: “I am delighted to have the support of our new investor The North West Fund for Biomedical and the ongoing support of our existing shareholder Fusion IP. The investment will also complement funding secured from the Biomedical Catalyst - a funding stream administered by the UK’s innovation agency, the Technology Strategy Board (TSB), to further develop Absynth’s product pipeline. With bacterial infections a major cause of death worldwide, Absynth’s lead programme focuses on infections caused by the bacterium Staphylococcus aureus including its more difficult-to-treat drug-resistant form, methicillin-resistant S.aureus (MRSA).Ībsynth’s novel antigens offer broad potential against a range of bacterial infections and form the basis of the company’s pipeline that includes vaccines to prevent Clostridium difficile (C.diff) and Streptococcus pyogenes infections.Ībsynth will use the investment to advance the Staphylococcus aureus programme to key pre-clinical milestones.

The North West Fund for Biomedical is part of the wider £155m North West Fund, financed jointly by the European Regional Development Fund and the European Investment Bank. Spinout Company secures £850,000 to develop vaccines against infectionĪ COMPANY working to develop vaccines and antibodies to treat bacterial infections has secured a £850,000 investment.Ībsynth Biologics Limited, a UK biotechnology spinout company from the University of Sheffield, has secured £400,000 from The North West Fund for Biomedical, managed by SPARK Impact as well as £450,000 from Fusion IP plc, the university commercialisation company.

Absynth biologics limited